STABLE-MATES : A Randomised Phase III study of sub-lobar resection (SR) versus Stereotactic Ablative Radiotherapy (SABR) in high risk patients with Stage I Non-Small cell Lung Cancer

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Multiple<Br/>Treatment TypesTypeMultiple
Treatment Types

ThreePhase Three

18-99Age 18-99

Lung<br/>CancersCancer LocationLung
Cancers

Multiple treatment types,Radiotherapy,Surgical | LungLung,Non-Small Cell Lung Cancer

Trial Overview Read MoreRead more

This phase III trial is comparing surgery and radiation therapy in the treatment of stage I Non-Small Cell (NSC) Lung Cancer.
 

This trial is treating patients with Non-Small Cell (NSC) Lung Cancer.

This is a radiotherapy and surgical trial.

You may be able to join this trial if:

  • Your cancer has not spread to other parts of the body.

You may be excluded from this trial if:

  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Randomised Phase III study of sub-lobar resection (SR) versus Stereotactic Ablative Radiotherapy (SABR) in high risk patients with Stage I Non-Small cell Lung Cancer

Other Non-Commercial Sponsor

University of Texas Southwestern Medical Center

Summary

Stereotactic Ablative Radiotherapy has been shown in single institution phase II and matched cohort studies to be effective at controlling primary early lung cancer. Recent pooled analysis of both the STARS and ROSEL randomized trials comparing SABR versus lobectomy have shown a significantly improved 3-year survival with SABR, giving further impetus for successful completion of a randomized trial . Pre-randomized trial- Patients will be screened and pre-randomized to either SR or SAbR. Informed consent will be obtained after patients are made aware of the randomized assignment. Despite pre-randomization prior to consent, patients maintain their right to accept or decline any/all study activities. Only consenting patients will be allowed to participate in study activities, including observation after either randomized treatments or observation after standard of care treatment, while those declining consent will be managed by their physician(s) off study.Patients will be accrued and followed for a minimum of 2-years after treatment.

Recruiting Hospitals Read MoreRead more

Peter MacCallum Cancer Centre
Parkville
Ms Lisa Selbie
Lisa.Selbie@petermac.org
(03) 8559 7388

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next